Mesoblast Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
80,958.00
119,368.00
5,671.30
101,856.10
45,544.90
Depreciation, Depletion & Amortization
1,120.00
1,955.00
3,012.30
4,053.60
3,420.10
Other Funds
1,170.00
9,605.00
1,067.80
7,218.70
3,584.00
Funds from Operations
77,727.00
127,018.00
120,726.50
108,352.10
85,283.40
Changes in Working Capital
4,134.00
5,309.00
197.90
18,241.70
11,526.30
Net Operating Cash Flow
81,861.00
121,709.00
120,924.40
126,593.80
96,809.70
Capital Expenditures
37,918.00
2,716.00
1,267.00
412.40
259.40
Purchase/Sale of Investments
1,483.00
939.00
1,106.20
-
-
Net Investing Cash Flow
40,809.00
5,612.00
2,373.30
188.30
1,488.00
Issuance/Reduction of Debt, Net
-
-
-
-
40,410.90
Net Financing Cash Flow
2,430.00
59,413.00
85,291.30
79,566.20
88,551.20
Net Change in Cash
118,915.00
52,252.00
40,901.80
47,035.60
10,322.10
Free Cash Flow
83,726.00
124,177.00
121,916.60
127,006.20
97,069.10
Deferred Taxes & Investment Tax Credit
3,281.00
-
119,135.20
17,768.30
39,574.60
Net Assets from Acquisitions
-
2,331.00
-
-
-
Other Sources
320.00
374.00
-
600.70
-
Change in Capital Stock
2,430.00
59,413.00
85,291.30
79,566.20
48,140.30
Exchange Rate Effect
1,325.00
15,656.00
2,895.40
196.20
575.60
Other Uses
1,728.00
-
-
-
1,228.60

About Mesoblast

View Profile
Address
55 Collins Street
Melbourne Victoria (VIC) 3000
Australia
Employees -
Website http://www.mesoblast.com
Updated 07/08/2019
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.